Hypercholesterolaemia induces early renal lesions characterized by upregulation of MMP-9 and iNOS and ETAR: Alleviated by a dual endothelin receptor antagonist CPU0213 and simvastatin

Journal of Pharmacy and Pharmacology

Volumn 61, Issue 6, 2009, Pages 775-780

  Luo, Lu ^a   Dai, De Zai ^a   Zheng, Yu Fen ^a   Dai, Yin ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Endothelin receptor antagonist; ET 1; Hypercholesterolaemia; iNOS; MMP 9; Simvastatin

Indexed keywords

CPU 0213; ENDOTHELIN A RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; GELATINASE B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDUCIBLE NITRIC OXIDE SYNTHASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; PROTEIN; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; CHOLESTEROL; CPU0213; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; KIDNEY DISEASE; KIDNEY INJURY; LIPID DIET; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; ANIMAL; BIOSYNTHESIS; BLOOD; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; KIDNEY; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; BODY WEIGHT; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; KIDNEY; KIDNEY DISEASES; MALE; MATRIX METALLOPROTEINASE 9; NITRIC OXIDE SYNTHASE TYPE II; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ENDOTHELIN A; RNA, MESSENGER; SIMVASTATIN; TRIGLYCERIDES; UP-REGULATION;

EID: 68849097104     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp/61.06.0010     Document Type: Article

References (39)

1. Crook ED et al. Lipid abnormalities and renal disease: is dyslipidemia a predictor of progression of renal disease? Am J Med Sci 2003; 325: 340-348.
2. Kes P. Lipid abnormalities in chronic renal failure, nephrotic syndrome and dialysis. Acta Med Croatica 2003; 55: 177-186.
3. Kume S et al. Role of altered renal lipid metabolism in the development of renal injury induced by a high-fat diet. J Am Soc Nephrol 2007; 18: 2715-2723.
4. Ruan XZ et al. Inflammation modifies lipid-mediated renal injury. Nephrol Dial Transplant 2003; 18: 27-32.
5. Kwan BCH et al. Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol 2007; 18: 1246-1261.
6. He HB et al. CPU0213, a novel endothelin receptor antagonist, ameliorates septic renal lesion by suppressing ET system and NF-kappaB in rats. Acta Pharmacol Sin 2006; 27: 1213-1221.
7. Avdagić N et al. The effects of inducible nitric oxide synthase inhibitor L-N6-(1-iminoethyl) lysine in gentamicin-induced acute tubular necrosis in rats. Bosn J Basic Med Sci 2007; 7: 345-351.
8. Doller A et al. Molecular mechanisms of cyclosporin A inhibition of the cytokine-induced matrix metalloproteinase-9 in glomerular mesangial cells. J Am Soc Nephrol 2007; 18: 581-592.
9. Baud L et al. Production of tumor necrosis factor by rat mesangial cells in response to bacterial lipopolysaccharide. Kidney Int 1989; 35: 1111-1118.
10. Mawatari K et al. Endothelin-1(1-31) levels are increased in atherosclerotic lesions of the thoracic aorta of hypercholesterolemic hamsters. Atherosclerosis 2003; 175: 203-212.
11. Sutherland AJ et al. The endothelin axis and gelatinase activity in alveolar macrophages after brain-stem death injury: a pilot study. J Heart Lung Transplant 2007; 26: 1040-1047.
12. Feng Y et al. Reversal of isoproterenol-induced downregulation of phospholamban and FKBP12.6 by CPU0213-mediated antagonism of endothelin receptors. Acta Pharmacol Sin 2007; 28(11): 1746-1754.
13. Xu J et al. The endothelin receptor antagonist CPU0213 is more effective than aminoguanidine to attenuate isoproterenolinduced vascular abnormality by suppressing overexpression of NADPH oxidase, ETA, ETB, and MMP9 in the vasculature. J Cardiovasc Pharmacol 2008; 52: 42-48.
14. Xu M et al. Protective effect of the endothelin antagonist CPU0213 against isoprenaline-induced heart failure by suppressing abnormal expression of leptin, calcineurin and SERCA2a in rats. J Pharm Pharmacol 2008; 60: 739-745.
15. Kirkby NS et al. The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol 2008; 153: 1105-1119.
16. Miloradović Z et al. Bosentan and losartan ameliorate acute renal failure associated with mild but not strong NO blockade. Nephrol Dial Transplant 2007; 22: 2476-2484.
17. Na T et al. Upregulation of leptin pathway correlates with abnormal expression of SERCA2a, phospholamban and the endothelin pathway in heart failure and reversal by CPU86017. Naunyn Schmiedebergs Arch Pharmacol 2007; 375: 39-49.
18. Xia QG et al. Improvement of chronic heart failure by dexamethasone is not associated with downregulation of leptin in rats. Acta Pharmacol Sin 2007; 28: 202-210.
19. Liu J, Rosner MH. Lipid abnormalities associated with endstage renal disease. Semin Dial 2006; 19: 32-40.
20. Barter P. et al., Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007; 357: 1301-1310.
21. Jawień J. New insights into immunological aspects of atherosclerosis. Pol Arch Med Wewn 2008; 118: 127-131.
22. Ritz E, Wanner C. Lipid changes and statins in chronic renal insufficiency. J Am Soc Nephrol 2006; 17: 226-230.
23. Chade AR et al. Simvastatin promotes angiogenesis and prevents microvascular remodeling in chronic renal ischemia. FASEB J 2006; 20: 1706-1708.
24. Neuhofer W, Pittrow D. Role of endothelin and endothelin receptor antagonists in renal disease. Eur J Clin Invest 2006; 36: 78-88.
25. Dhaun N et al. Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease. Nephrol Dial Transplant 2007; 22: 3228-3234.
26. Dhaun N et al. The pharmacokinetic profile of sitaxsentan, a selective endothelin receptor antagonist, in varying degrees of renal impairment. Br J Clin Pharmacol 2007; 64: 733-737.
27. Touyz RM, Schiffrin EL. Role of endothelin in human hypertension. Can J Physiol Pharmacol 2003; 81: 533-541.
28. Sukhija R et al. Effect of statins on the development of renal dysfunction. Am J Cardiol 2008; 101: 975-979.
29. Strippoli GF et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. Br Med J 2008; 336: 645-651.
30. Mastalerz-Migas A et al. Comparison of a statin vs. hypolipidemic diet on the oxidant status in hemodialyzed patients with chronic renal failure. J Physiol Pharmacol 2007; 58: 363-370.
31. Qi MY et al. A novel endothelin receptor antagonist CPU0213 improves diabetic cardiac insufficiency attributed to upregulation of the expression of FKBP12. 6, SERCA2a, and PLB in rats. J Cardiovasc Pharmacol 2006; 47(6): 729-735.
32. Xu M et al. Normalizing NOX contributes to attenuating diabetic nephropathy by a dual endothelin receptor antagonist CPU0213 in rats. Am J Nephropathy 2008; 29: 252-256.
33. Song HJ et al. Reactive oxygen species mediate ET-1-induced activation of ERK1/2 signaling in cultured feline esophageal smooth muscle cells. Arch Pharm Res 2007; 30: 1080-1087.
34. Luo L et al. Effect of the endothelin receptor antagonist CPU0213, and its modulation by rifampin, on cardiac and vascular tissue following chronic isoproterenol treatment. Clin Exp Pharmacol Physiol 2008; 35: 757-765.
35. Chang HR et al. Relationships between circulating matrix metalloproteinase-2 and -9 and renal function in patients with chronic kidney disease. Clinica Chimica Acta 2006; 366: 243-248.
36. Wilson WR et al. HMG-CoA reductase inhibitors (statins) decrease MMP-3 and MMP-9 concentrations in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2005; 30: 259-262.
37. Tian YC et al. Epidermal growth factor and transforming growth factor-β1 enhance HK-2 cell migration through a synergistic increase of matrix metalloproteinase and sustained activation of ERK signaling pathway. Exp Cell Res 2007; 313: 2367-2377.
38. Diepeveen SH et al. Cholesterol in end-stage renal disease: the good, the bad or the ugly? Neth J Med 2008; 66: 53-61.
39. McCullough PA, Rocher LR. Statin therapy in renal disease: harmful or protective? Curr Diab Rep 2007; 7: 467-473.